BOISE, ID — Idaho Attorney General Raúl Labrador announced Tuesday that the state could receive up to $2.6 million as part of a nationwide $720 million opioid settlement with eight drug manufacturers.

The settlement targets companies accused of contributing to the opioid crisis by prioritizing profits and producing high volumes of opioid medications. Idaho’s potential share is based on both the volume of opioids distributed in the state and the prevalence of opioid use disorder among residents.

“These companies have prioritized profits over the lives of Idaho families, and we’re holding them accountable for that,” Labrador stated. “Since taking office, we’ve secured nearly $60 million for Idaho from opioid manufacturers.”

Since 2023, Labrador has secured a total of $58.6 million in opioid-related settlements for Idaho. Under the state’s distribution model, 40% of Idaho’s share will go to the Idaho Opioid Fund, 40% to cities and counties, and 20% to the state’s seven public health districts.

The eight manufacturers named in the settlement are Mylan (now part of Viatris), Hikma, Amneal, Apotex, Indivior, Sun, Alvogen, and Zydus. Seven of those companies—excluding Indivior—have agreed to stop promoting opioids, discontinue producing pills with more than 40 mg of oxycodone, and implement systems to monitor and report suspicious orders.

Indivior has committed to halting the manufacture and sale of opioid products for the next decade but will still be permitted to market and sell treatments for opioid use disorder.

The agreement is contingent on participation by local governments during the settlement sign-on period.